Thursday, 26 April 2018 - 6:25
  • it
  • de
  • en
  • fr

Lundbeck

Lundbeck acquires Netherlands-based Prexton Therapeutics for €955m

Denmark-based Lundbeck A/S has announced today it has acquired Netherlands-based Prexton Therapeutics BV for €955m. Specifically, the agreement includes an upfront €100m payment, plus an additional €805m if Prexton reaches precise commercial targets. Prexton’s main asset is probably foliglurax, a…